Connect with us

Meridia (sibutramine)


Sibutramine (or MERIDIA®) was mainly prescribed to treat obesity.

Status: DISCONTINUED

Class: Anorectic, Serotonin-norepinephrine Reuptake Inhibitor (SNRI),

FDA Approval: 1997

Dosage Forms: 5 mg, 10 mg, 15 mg

Biological Half-life: 1 hour (sibutramine), 14 hours (M1), 16 hours (M2)

Side Effects: Dizziness, blurred vision, dry mouth, nausea, insomnia, constipation, appetite changes, flushing, muscle/joint pain, high blood pressure, tachycardia

Routes of Administration: Oral

Pregnancy Category: C (US)

  www.fda.gov

Like Us

Advertisement
Advertisement